These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 31870787)
1. Comparison of the Intestinal Drug Permeation and Accumulation Between Normal Human Intestinal Tissues and Human Intestinal Tissues With Ulcerative Colitis. Nakai D; Miyake M; Hashimoto A J Pharm Sci; 2020 Apr; 109(4):1623-1626. PubMed ID: 31870787 [TBL] [Abstract][Full Text] [Related]
2. Establishment of novel prediction system of intestinal absorption in humans using human intestinal tissues. Miyake M; Toguchi H; Nishibayashi T; Higaki K; Sugita A; Koganei K; Kamada N; Kitazume MT; Hisamatsu T; Sato T; Okamoto S; Kanai T; Hibi T J Pharm Sci; 2013 Aug; 102(8):2564-71. PubMed ID: 23686795 [TBL] [Abstract][Full Text] [Related]
3. Prediction of drug intestinal absorption in human using the Ussing chamber system: A comparison of intestinal tissues from animals and humans. Miyake M; Koga T; Kondo S; Yoda N; Emoto C; Mukai T; Toguchi H Eur J Pharm Sci; 2017 Jan; 96():373-380. PubMed ID: 27721045 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous Prediction of Intestinal Absorption and Metabolism Using the Mini-Ussing Chamber System. Kondo S; Miyake M J Pharm Sci; 2019 Jan; 108(1):763-769. PubMed ID: 30389567 [TBL] [Abstract][Full Text] [Related]
5. Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. Rozehnal V; Nakai D; Hoepner U; Fischer T; Kamiyama E; Takahashi M; Yasuda S; Mueller J Eur J Pharm Sci; 2012 Aug; 46(5):367-73. PubMed ID: 22418036 [TBL] [Abstract][Full Text] [Related]
6. The change of the electrophysiological parameters using human intestinal tissues from ulcerative colitis and Crohn's disease. Nakai D; Miyake M J Pharmacol Sci; 2022 Oct; 150(2):90-93. PubMed ID: 36055756 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of intestinal metabolism and absorption using the Ussing chamber system equipped with intestinal tissue from rats and dogs. Miyake M; Kondo S; Koga T; Yoda N; Nakazato S; Emoto C; Mukai T; Toguchi H Eur J Pharm Biopharm; 2018 Jan; 122():49-53. PubMed ID: 28974435 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous Prediction Method for Intestinal Absorption and Metabolism Using the Mini-Ussing Chamber System. Kondo S; Miyake M Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140073 [TBL] [Abstract][Full Text] [Related]
9. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage. Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624 [TBL] [Abstract][Full Text] [Related]
10. KFL2 participates in the development of ulcerative colitis through inhibiting inflammation via regulating cytokines. Wang ZL; Wang YD; Wang K; Li JA; Li L Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4941-4948. PubMed ID: 30070340 [TBL] [Abstract][Full Text] [Related]
11. Increased membrane permeation and blood concentration of 6-carboxyfluorescein associated with dysfunction of paracellular route barrier in the small intestine of ulcerative colitis model rats. Kumagai M; Ishii M; Morimoto K; Tomita M Biopharm Drug Dispos; 2020 Mar; 41(3):91-100. PubMed ID: 32043274 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. Sjöberg Å; Lutz M; Tannergren C; Wingolf C; Borde A; Ungell AL Eur J Pharm Sci; 2013 Jan; 48(1-2):166-80. PubMed ID: 23103351 [TBL] [Abstract][Full Text] [Related]
13. Human intestinal fluid factors affecting intestinal drug permeation in vitro. Riethorst D; Brouwers J; Motmans J; Augustijns P Eur J Pharm Sci; 2018 Aug; 121():338-346. PubMed ID: 29902511 [TBL] [Abstract][Full Text] [Related]
14. [Expression of phosphatidylinositol 3-kinase and effects of wortmannin on the expression of tumor necrosis factor-alpha in ulcerative colitis]. Huang XL; Yi WQ; Zhang M; Ouyang Q; Gan HT Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):379-82. PubMed ID: 17456377 [TBL] [Abstract][Full Text] [Related]
16. Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis. Erdmann P; Bruckmueller H; Martin P; Busch D; Haenisch S; Müller J; Wiechowska-Kozlowska A; Partecke LI; Heidecke CD; Cascorbi I; Drozdzik M; Oswald S J Pharm Sci; 2019 Feb; 108(2):1035-1046. PubMed ID: 30267783 [TBL] [Abstract][Full Text] [Related]
17. [Effect of Qingchang Suppository on intestinal permeability in rats with ulcerative colitis]. Lu L; Xie JQ Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Oct; 30(10):1087-90. PubMed ID: 21066896 [TBL] [Abstract][Full Text] [Related]
18. The Ussing Chamber Assay to Study Drug Metabolism and Transport in the Human Intestine. Kisser B; Mangelsen E; Wingolf C; Partecke LI; Heidecke CD; Tannergren C; Oswald S; Keiser M Curr Protoc Pharmacol; 2017 Jun; 77():7.17.1-7.17.19. PubMed ID: 28640954 [TBL] [Abstract][Full Text] [Related]
19. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Büning C; Geissler N; Prager M; Sturm A; Baumgart DC; Büttner J; Bühner S; Haas V; Lochs H Inflamm Bowel Dis; 2012 Oct; 18(10):1932-9. PubMed ID: 22344959 [TBL] [Abstract][Full Text] [Related]
20. A Novel Topical PPARγ Agonist Induces PPARγ Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models. Da Silva S; Keita ÅV; Mohlin S; Påhlman S; Theodorou V; Påhlman I; Mattson JP; Söderholm JD Inflamm Bowel Dis; 2018 Mar; 24(4):792-805. PubMed ID: 29529198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]